The fact that the Gila monster slowly chews its venom into its targets might pale in comparison to how it might have inspired the birth of Ozempic.
getty
When most people picture a venomous reptile, they picture a snake with its fangs folding forward and a lightning-fast strike. It’s a clean, almost clinical image where venom is used almost always as a precision instrument. The Gila monster (Heloderma suspectum), however, does not subscribe to that image.
The only venomous lizard native to the United States doesn’t inject anything. It bites down and holds, working its jaw in a slow, deliberate chewing motion while venom seeps upward through grooved teeth and into the wound. The whole process is unhurried, nothing like the elegant hypodermic strike of a viper. And yet this lizard has carried its venom system virtually unchanged for at least 30 million years.
Two explanations, not mutually exclusive, have emerged from the literature for why the Gila monster developed this approach rather than evolving the hollow fang of a rattlesnake. The first comes down to diet. H. suspectum feeds primarily on eggs, nestlings and the occasional small mammal — prey that is passive, often immobile and doesn’t require subduing quickly. When your food can’t run, the pressure to evolve a fast delivery system largely disappears.
The second explanation, supported by morphological and behavioral evidence, is that the venom functions primarily as a deterrent against predators, not a predatory tool. A sustained, painful bite that pumps in toxin over time is arguably more effective as a warning than a quick strike.
The two explanations converge on the same conclusion: the chewing system isn’t primitive. It’s fit for purpose. And as it turns out, this unusual venom system would eventually lead scientists to a molecule that helped inspire the development of modern GLP-1 drugs, including Ozempic — one of the most influential pharmaceutical breakthroughs of the 21st century.
Unlike snakes, whose venom glands sit in the upper jaw and connect to hollow or partially grooved fangs, the Gila monster’s venom apparatus is located in the lower jaw.
The gland, as explained by a 2013 paper, is a four-lobed structure divided by fibrous tissue, positioned in the anterior portion of the mandible. From there, venom flows into a dental sac adjacent to the teeth and travels upward along the external grooves of deeply channeled, lance-shaped teeth through capillary action, not pressure. This is precisely why it has to chew. The teeth themselves are pleurodont, or fused to the inner surface of the jawbone, and periodically shed and replaced throughout the lizard’s life. The largest teeth sit nearest the venom duct discharge point. The authors of the study identified two distinct bites:
In other words, the severity of a Gila monster bite is directly proportional to how long the lizard holds on.
In terms of raw potency, Gila monster venom is roughly comparable to that of the western diamondback rattlesnake. In terms of lethality to humans, it’s almost negligible because the delivery system is so “inefficient” that envenomation severe enough to cause death is essentially unrecorded in the clinical literature. The venom is real, but the threat to humans, at least in practice, is not.
This is where the story takes a very interesting turn. In a seminal 1990 study published in the Mount Sinai Journal of Medicine, endocrinologist Dr. John Eng, working at the Veterans Administration Center in the Bronx, identified a peptide in Gila monster venom he called exendin-4.
Fascinatingly, it mimicked glucagon-like peptide-1, known famously today as a GLP-1: a hormone the human pancreas uses to stimulate insulin release after meals. The problem with GLP-1 as a drug candidate had always been its half-life: less than two minutes in the bloodstream before the enzyme DPP-4 degrades it. A drug with a two-minute window is barely a drug at all.
Exendin-4 shares only 53% amino acid sequence identity with human GLP-1, and that difference turned out to be everything. The result is a molecule that activates the same receptor as GLP-1, but stays active far longer. The Gila monster hadn’t evolved this peptide to help diabetic humans; it almost certainly serves a physiological role in the lizard’s own fasting metabolism. But the pharmacological consequence was profound.
Synthetic exendin-4 became exenatide, marketed as Byetta, and in 2005, it became the first GLP-1 receptor agonist approved by the FDA for the treatment of type 2 diabetes. Clinical trials showed reductions in HbA1c of 0.8–1.0 percentage points alongside meaningful weight loss.
The same biological mechanism (i.e., GLP-1 receptor agonism) now underpins semaglutide, sold under the names Ozempic, Mounjaro and Wegovy — arguably the most culturally significant drug class of the past decade.
Of course, the Gila monster didn’t invent GLP-1 drugs. What it did was show researchers what a durable GLP-1 agonist could look like. That’s a meaningful distinction, and not a small contribution.
The Gila monster is listed as Near Threatened on the IUCN Red List. It is legally protected in Arizona, Nevada, Utah and New Mexico. It is illegal to collect, kill or trade. But sadly, none of that has fully insulated it from pressure.
The primary threats are familiar: habitat loss from urban expansion across the Sonoran and Mojave deserts, road mortality and illegal collection for the exotic pet trade. A 2025 peer-reviewed study in Ecology and Evolution modeled Gila monster habitat suitability across the Mojave under multiple IPCC climate scenarios and found that suitable habitat contracts substantially under high-emission projections, compounded by the species’ limited dispersal ability and specialized shelter requirements.
The Gila monster spends up to 95% of its life underground. It eats perhaps three to five large meals per year, storing energy almost entirely in its tail — a structure researchers measure as a proxy for body condition in the field. It is, in most respects, invisible.
A lizard that chews its venom in rather than injecting it, sleeps through most of its own existence and whose biology gave medicine one of its most important drug classes in modern history. Most Americans will spend their entire lives without ever seeing one. That, it seems worth pointing out, is both a loss and a reason to pay closer attention.
Did you know these interesting facts about the gila monster already? Take my fun Reptile & Amphibian IQ Test to really put your knowledge to the test.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。